Company has received purchase orders from various entities for supply of it''s products.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Drugs Ltd has received significant purchase orders during December 2025 for supply of pharmaceutical products, with an aggregate value of approximately ₹14.71 Crores. The orders come from several entities, including Tamil Nadu Medical Services Corporation (TNMSC) with 6 purchase orders, the Directorate General of Health Services (DGHS), TNMSC's Mudhalvar Marundhagam Scheme with 32 purchase orders, and Telangana State Medical Services & Infrastructure Development Corporation (TGMSIDC), along with other entities. All orders are domestic and involve supply of various pharmaceutical products, to be executed within the next 45 to 60 days. The company has confirmed that no promoter or group company has any interest in the entities awarding these orders, and the transactions are not related party transactions.
This is a positive development for Concord Drugs as it strengthens the order book with institutional and government-backed demand for its pharmaceutical products. The fact that the order value exceeds the company's internal materiality threshold signals meaningful business contribution, though the short 45-60 day execution window suggests revenue recognition is near-term rather than long-cycle.